An mRNA-based flu vaccine designed to offer long-lasting protection against a broad range of influenza viruses is now in a phase I clinical trial, the National Institutes of Health announced this week.The trial brings the remarkable success of the mRNA vaccine platform to the long-standing efforts to develop a universal flu vaccine.
#people #responsible #researchers #vaccination #news-release #infectious-diseases #immune-system #duke-university
[
add
]
[
|
|
...
]